Leonard Gomella, MD, the Bernard W. Godwin, Jr. Professor of Prostate Cancer and Chairman of the Department of Urology at Jefferson Medical College, sees the increasing number of FDA approvals for immunotherapies in metastatic cancers as a catalyst for many new clinical trials examining the drugs’ potentials for treating superficial and first-occurrence disease in patients with bladder cancer.